Preclinical Programs

Our portfolio of projects includes numerous targets governing signal transduction in cancer cells, DNA repair mechanisms, and other processes believed to be key for cancer cells growth and maintenance.

In particular Nerviano Medical Sciences has an ALK inhibitor approaching filing of an IND, a TRKA inhibitor in late preclinical development and programs aimed at targeting HSP90, PARP1, MPS1 and FLT3/KIT, as well as additional undisclosed targets.

Selected references

  • In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori, EORTC Meeting 2011: Molecular Targets and Cancer Therapeutics.
  • Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer, EORTC-NCI-AACR International Congress 2010, 22nd: November 17(Abs 102)
  • NMS-P118, a Parp-1 selective inhibitor with efficacy in DNA repair deficient tumor models. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany. 2010.
  • In vitro and in vivo characterization of selective orally available Parp-1 inhibitors with demonstrated antitumor efficacy in BRCA negative cancer models, American Association for Cancer Research Annual Meeting 2010,101st: April 18 (Abs 691)
  • Pharmacological characterization of NMS-P506, a novel second generation HSP90 inhibitor. AACR-NCI-EORTC International Congress 2010 (Abs 147)
  • Synthesis and SAR of New Pyrazolo[4,3-h] quinazoline -3-carboxamide Derivatives as Potent and Selective MPS1 Kinase Inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 4507-4511
  • Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase, Cancer Research 2010,70:24 (10255-10264
  • Identification and characterization of new highly selective and potent BRAF inhibitors, American Association for Cancer Research Annual Meeting 2010,101st:April 19 (Abs 2522)
  • NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations, EORTC Meeting 2011: Molecular Targets and Cancer Therapeutics